Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Novel and emerging therapies for cholestatic liver diseases.

Goldstein J, Levy C.

Liver Int. 2018 May 14. doi: 10.1111/liv.13880. [Epub ahead of print] Review.

PMID:
29758112
2.

Cholestatic Itch Management.

Mittal A.

Curr Probl Dermatol. 2016;50:142-8. doi: 10.1159/000446057. Epub 2016 Aug 23. Review.

PMID:
27578083
3.

Novel Aspects in the Management of Cholestatic Liver Diseases.

Chazouillères O.

Dig Dis. 2016;34(4):340-6. doi: 10.1159/000444544. Epub 2016 May 11.

PMID:
27170387
4.

The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics.

Ridlon JM, Bajaj JS.

Acta Pharm Sin B. 2015 Mar;5(2):99-105. doi: 10.1016/j.apsb.2015.01.006. Epub 2015 Feb 9. Review.

5.

Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR.

Wunsch E, Klak M, Wasik U, Milkiewicz M, Blatkiewicz M, Urasinska E, Barbier O, Bielicki D, Bogdanos DP, Elias E, Milkiewicz P.

J Immunol Res. 2015;2015:571353. doi: 10.1155/2015/571353. Epub 2015 Oct 4.

6.

Advances in pathogenesis and management of pruritus in cholestasis.

Kremer AE, Bolier R, van Dijk R, Oude Elferink RP, Beuers U.

Dig Dis. 2014;32(5):637-45. doi: 10.1159/000360518. Epub 2014 Jul 14. Review.

PMID:
25034299
7.

Nuclear receptors CAR and PXR; therapeutic targets for cholestatic liver disease.

Kakizaki S, Takizawa D, Tojima H, Horiguchi N, Yamazaki Y, Mori M.

Front Biosci (Landmark Ed). 2011 Jun 1;16:2988-3005. Review.

PMID:
21622216
8.

Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice.

Jahnel J, Fickert P, Langner C, Högenauer C, Silbert D, Gumhold J, Fuchsbichler A, Trauner M.

Liver Int. 2009 Oct;29(9):1316-25. doi: 10.1111/j.1478-3231.2009.02044.x. Epub 2009 Jun 24.

PMID:
19558576
9.

PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics.

Zhang B, Xie W, Krasowski MD.

Pharmacogenomics. 2008 Nov;9(11):1695-709. doi: 10.2217/14622416.9.11.1695. Review.

10.

Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?

Beuers U, Kullak-Ublick GA, Pusl T, Rauws ER, Rust C.

Clin Rev Allergy Immunol. 2009 Feb;36(1):52-61. doi: 10.1007/s12016-008-8085-y. Review.

11.

Coordinated defence and the liver.

Elias E, Mills CO.

Clin Med (Lond). 2007 Apr;7(2):180-4.

PMID:
17491508
12.

Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis.

Karlsen TH, Lie BA, Frey Frøslie K, Thorsby E, Broomé U, Schrumpf E, Boberg KM.

Gastroenterology. 2006 Sep;131(3):781-7.

PMID:
16952547

Supplemental Content

Loading ...
Support Center